Epic Systems Slammed by Antitrust Lawsuit
Particle Health accuses Epic Systems of antitrust violations in the EHR market
Particle Health accuses Epic Systems of antitrust violations in the EHR market
Healthcare advocates warn that a new CMS rule on Medicaid work requirement exemptions could increase red tape and cause eligible people to lose coverage. The post Will CMS’ Last-Minute Medicaid Work Requirement Changes Cause More Harm? appeared first on MedCity News.
At a moment when medication therapy for sickle cell disease (SCD) leaves too many behind and widespread access to curative gene therapies still lies in the distant future, automated red blood cell exchange is experiencing renewed interest. To improve patients’ lives, a broad commitment is needed to expand access to transfusion therapies. The post Beyond…
Non-binding offers for Galapagos’s cell therapies assets came mostly from financial investors, and none offered sufficient terms or financing to support the business, the company said. Galapagos’s exit from cell therapy work will lead to site closures in Europe, China, and the U.S. The post Galapagos to Wind Down Cell Therapy Business After Search for…
As SUD IMD waiver evaluations and renewals are becoming available, states face a shifting Medicaid and policy and waiver landscape. This brief examines findings from the first available summative evaluations for SUD IMD waivers and what they show about progress toward meeting goals and milestones.
The post National Vaccination Day, Importance of Vaccines appeared first on Medifyhome.
In a new brief, the Purchaser Business Group on Health called for policy changes that address healthcare costs and improve access to high-quality care. The post PBGH Calls on New Congress and Administration to Improve Employee Healthcare in 2 Key Areas appeared first on MedCity News.
The rise of metabolic gene therapies represents a critical juncture for benefits management. These treatments offer genuine hope for patients with serious conditions, but they also pose significant financial challenges. The post Preparing Benefits For the Next Wave: Gene Therapy Medications appeared first on MedCity News.
Merus brings Genmab a bispecific antibody in two pivotal studies for head and neck cancer. Genmab, which had long developed drugs under partnerships with larger companies, is now pursuing a strategy of developing and commercializing medications it fully owns. The post Genmab to Pay $8B to Get Its Hands on Merus Head & Neck Cancer…
National Endowment for the Humanities funds Center for Humanities-based Health AI Innovation